544 related articles for article (PubMed ID: 24763289)
1. Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients.
LaDuca H; Stuenkel AJ; Dolinsky JS; Keiles S; Tandy S; Pesaran T; Chen E; Gau CL; Palmaer E; Shoaepour K; Shah D; Speare V; Gandomi S; Chao E
Genet Med; 2014 Nov; 16(11):830-7. PubMed ID: 24763289
[TBL] [Abstract][Full Text] [Related]
2. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
4. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
Feliubadaló L; López-Fernández A; Pineda M; Díez O; Del Valle J; Gutiérrez-Enríquez S; Teulé A; González S; Stjepanovic N; Salinas M; Capellá G; Brunet J; Lázaro C; Balmaña J;
Int J Cancer; 2019 Nov; 145(10):2682-2691. PubMed ID: 30927264
[TBL] [Abstract][Full Text] [Related]
5. The NCCN Criterion "Young Age at Onset" Alone is Not an Indicator of Hereditary Breast Cancer in Iranian Population.
Ebrahimi E; Sellars E; Shirkoohi R; Harirchi I; Ghiasvand R; Mohebbi E; Zendehdel K; Akbari MR
Cancer Prev Res (Phila); 2019 Nov; 12(11):763-770. PubMed ID: 31451522
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes.
Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J;
Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971
[TBL] [Abstract][Full Text] [Related]
7. Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines.
Neben CL; Zimmer AD; Stedden W; van den Akker J; O'Connor R; Chan RC; Chen E; Tan Z; Leon A; Ji J; Topper S; Zhou AY
J Mol Diagn; 2019 Jul; 21(4):646-657. PubMed ID: 31201024
[TBL] [Abstract][Full Text] [Related]
8. Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer.
Feliubadaló L; Tonda R; Gausachs M; Trotta JR; Castellanos E; López-Doriga A; Teulé À; Tornero E; Del Valle J; Gel B; Gut M; Pineda M; González S; Menéndez M; Navarro M; Capellá G; Gut I; Serra E; Brunet J; Beltran S; Lázaro C
Sci Rep; 2017 Jan; 7():37984. PubMed ID: 28050010
[TBL] [Abstract][Full Text] [Related]
9. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program.
Bunnell AE; Garby CA; Pearson EJ; Walker SA; Panos LE; Blum JL
J Genet Couns; 2017 Feb; 26(1):105-112. PubMed ID: 27276934
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing.
Susswein LR; Marshall ML; Nusbaum R; Vogel Postula KJ; Weissman SM; Yackowski L; Vaccari EM; Bissonnette J; Booker JK; Cremona ML; Gibellini F; Murphy PD; Pineda-Alvarez DE; Pollevick GD; Xu Z; Richard G; Bale S; Klein RT; Hruska KS; Chung WK
Genet Med; 2016 Aug; 18(8):823-32. PubMed ID: 26681312
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients.
Lincoln SE; Kobayashi Y; Anderson MJ; Yang S; Desmond AJ; Mills MA; Nilsen GB; Jacobs KB; Monzon FA; Kurian AW; Ford JM; Ellisen LW
J Mol Diagn; 2015 Sep; 17(5):533-44. PubMed ID: 26207792
[TBL] [Abstract][Full Text] [Related]
13. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
[TBL] [Abstract][Full Text] [Related]
14. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients.
LaDuca H; Polley EC; Yussuf A; Hoang L; Gutierrez S; Hart SN; Yadav S; Hu C; Na J; Goldgar DE; Fulk K; Smith LP; Horton C; Profato J; Pesaran T; Gau CL; Pronold M; Davis BT; Chao EC; Couch FJ; Dolinsky JS
Genet Med; 2020 Feb; 22(2):407-415. PubMed ID: 31406321
[TBL] [Abstract][Full Text] [Related]
15. Germline whole genome sequencing in adults with multiple primary tumors.
Wang Y; Ding Q; Prokopec S; Farncombe KM; Bruce J; Casalino S; McCuaig J; Szybowska M; van Engelen K; Lerner-Ellis J; Pugh TJ; Kim RH
Fam Cancer; 2023 Oct; 22(4):513-520. PubMed ID: 37481477
[TBL] [Abstract][Full Text] [Related]
16. Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO.
Hoffman TL; Kershberg H; Goff J; Holmquist KJ; Haque R; Alvarado M
Fam Cancer; 2023 Apr; 22(2):225-235. PubMed ID: 36261688
[TBL] [Abstract][Full Text] [Related]
17. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.
DiNardo CD; Routbort MJ; Bannon SA; Benton CB; Takahashi K; Kornblau SM; Luthra R; Kanagal-Shamanna R; Medeiros LJ; Garcia-Manero G; M Kantarjian H; Futreal PA; Meric-Bernstam F; Patel KP
Cancer; 2018 Jul; 124(13):2704-2713. PubMed ID: 29682723
[TBL] [Abstract][Full Text] [Related]
18. Advances in the diagnosis of hereditary kidney cancer: Initial results of a multigene panel test.
Nguyen KA; Syed JS; Espenschied CR; LaDuca H; Bhagat AM; Suarez-Sarmiento A; O'Rourke TK; Brierley KL; Hofstatter EW; Shuch B
Cancer; 2017 Nov; 123(22):4363-4371. PubMed ID: 28787086
[TBL] [Abstract][Full Text] [Related]
19. Patients Tested at a Laboratory for Hereditary Cancer Syndromes Show an Overlap for Multiple Syndromes in Their Personal and Familial Cancer Histories.
Saam J; Arnell C; Theisen A; Moyes K; Marino I; Roundy KM; Wenstrup RJ
Oncology; 2015; 89(5):288-93. PubMed ID: 26315041
[TBL] [Abstract][Full Text] [Related]
20. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
